费内伦的心脏保护作用与抑制心肌积累在阿尔多斯特/盐载大鼠中相关
Asadur Rahman1, Tatsuya Sawano2, Kento Kitada1
1Department of Pharmacology, Faculty of Medicine Kagawa University Takamatsu Kagawa Japan.
Journal of the American Heart Association
|March 4, 2026
概括
菲内伦通过减少心脏中的积和炎症来预防心脏功能障碍. 这种非类固醇矿物质皮质类受体对抗剂可以防止不良的心脏重塑和心室功能障碍.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 费内伦是一种非类固醇矿物质皮质类受体对抗剂,在临床试验中显示出心血管保护作用.
- 在预防心血管损伤方面,费内伦的确切作用机制需要进一步阐明.
研究的目的:
- 在大鼠模型中,研究芬二对心肌损伤和积的影响.
- 为了探索finerenone对心脏重塑,功能障碍和炎症的影响.
主要方法:
- 雄性斯普拉格 - 达利大鼠接受了非切除术,并接受了长期的阿尔多素输液和盐加载4周.
- 施用了芬瑞治疗 (10 mg/kg),随后进行了心声扫描,基因表达分析和组织含量评估.
- 分析了心脏组织中的巨细胞的招募和两极分化,以及使用RAW264.7细胞的体外试验.
主要成果:
- 阿尔多斯特/盐装载的老鼠表现出不良的心脏重塑和心室功能障碍,而费内伦完全阻止了这种情况.
- 费内伦治疗减弱了左心室含量升高,并抑制了巨细胞的招募和M1极化.
- 在体外,finerenone在巨细胞系中降低了阿尔多/盐诱导的M1标记物,增加了M2标记物.
结论:
- 菲内伦通过抑制心肌积累的来抑制阿尔多素/盐诱导的心脏功能障碍.
- 菲内伦减轻了巨细胞介导的炎症,防止了不良的心脏重塑和功能障碍.
- 这些发现突出了菲内伦在管理与矿物质皮质体受体过度激活相关的条件中的潜在治疗作用.
更多相关视频
08:505/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
24.5K
09:47A Rat Model of Ventricular Fibrillation and Resuscitation by Conventional Closed-chest Technique
Published on: April 26, 2015
16.4K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.7K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
2.5K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.5K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
01:30Heart Failure V: Medical Management
439
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
439